Bortezomib, which is being launched immediately, is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is for adult patients with mantle cell lymphoma (cancer of lymph nodes).
Aurobindo Pharma on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection used to treat certain types of cancer. The approval by the US Food and Drug Administration (USFDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, Aurobindo Pharma said in a regulatory filing. The product is the generic version of reference listed drug Velcade of Takeda Pharmaceuticals USA Inc.
Recommended ArticlesView All
'Elephant in the room' — Finance Minister red-flags gold smuggling
IST2 Min(s) Read
The product is being launched immediately, it added. Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said.
The approved product has a market size of $1.172 billion for the 12 months ended March 2022, the company said citing IQVIA data.